Clinical and Economic Value of Reducing Antimicrobial Resistance in the Management of Hospital-Acquired Infections with Limited Treatment Options in Greece

Myrto Barmpouni; Jason P Gordon; Ryan L Miller; James W Dennis; Vassilis Grammelis; Aris Rousakis; Kyriakos Souliotis; Garyphallia Poulakou; George L Daikos; Amer Al-Taie

doi:10.1007/s40121-023-00837-7

Clinical and Economic Value of Reducing Antimicrobial Resistance in the Management of Hospital-Acquired Infections with Limited Treatment Options in Greece

Infect Dis Ther. 2023 Jul;12(7):1891-1905. doi: 10.1007/s40121-023-00837-7. Epub 2023 Jul 6.

Authors

Affiliations

¹ Pfizer Hellas, Athens, Greece.
² Health Economics and Outcomes Research Ltd., Cardiff, UK.
³ Faculty of Social and Political Sciences, University of Peloponnese, Corinth, Greece.
⁴ Health Policy Institute, Athens, Greece.
⁵ 3rd Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria General Hospital, Athens, Greece.
⁶ National and Kapodistrian University of Athens, Athens, Greece.
⁷ Pfizer R&D, Pfizer Ltd, Dorking Road, Tadworth, KT20 7NT, UK. Amer.Taie@Pfizer.com.

Abstract

Introduction: Antimicrobial resistance (AMR) is a major public health threat worldwide. Greece has the highest burden of infections due to antibiotic-resistant bacteria among European Union/European Economic Area (EU/EEA) countries. One of the most serious AMR threats in Greece is hospital-acquired infections (HAIs) with limited treatment options (LTO) caused by resistant gram-negative pathogens. Thus, this study sought to estimate the current AMR burden in Greece and the value of reducing AMR to gram-negative pathogens for the Greek healthcare system.

Methods: The current model was adapted from a previously published and validated model of AMR to investigate the overall and AMR-specific burden of treating the most common HAIs with LTO in Greece and scenarios to demonstrate the benefits associated with reducing AMR levels from a third-party payer perspective. Clinical and economic outcomes were estimated over a 10-year time horizon; life years (LYs) and quality-adjusted life years (QALYs) were calculated over a lifetime (based on the annual number of infections over 10 years) at a willingness-to-pay of €30,000 per QALY gained and a 3.5% discount rate.

Results: In Greece, the current AMR levels in HAIs with LTO caused by four gram-negative pathogens account for > 316,000 hospital bed days, €73 million in hospitalisation costs, and > 580,000 LYs and 450,000 QALYs lost over 10 years. The monetary burden is estimated at €13.9 billion. A reduction in current AMR levels by 10-50% results in clinical and economic benefit; 29,264-151,699 bed days may be saved, leading to decreased hospitalisation costs (€6.8 million-€35.3 million) and a gain in LYs (85,328-366,162) and QALYs (67,421-289,331), associated with a monetary benefit of between €2.0 billion and €8.7 billion.

Conclusion: This study shows the substantial clinical and economic burden AMR represents to the Greek healthcare system and the value that can be achieved by effectively reducing AMR levels.

Keywords: Antimicrobial resistance; Economic evaluation; Greece; Hospital-acquired infections; Infectious disease; Limited treatment options; National action plan.